CN1720977A - Female nutritive tonic capsule - Google Patents
Female nutritive tonic capsule Download PDFInfo
- Publication number
- CN1720977A CN1720977A CNA2004100263338A CN200410026333A CN1720977A CN 1720977 A CN1720977 A CN 1720977A CN A2004100263338 A CNA2004100263338 A CN A2004100263338A CN 200410026333 A CN200410026333 A CN 200410026333A CN 1720977 A CN1720977 A CN 1720977A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- examples
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 27
- 230000000050 nutritive effect Effects 0.000 title 1
- 230000001256 tonic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 93
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000002994 raw material Substances 0.000 claims description 29
- 108010052008 colla corii asini Proteins 0.000 claims description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 241000545442 Radix Species 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 241001127714 Amomum Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000010894 Artemisia argyi Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000282461 Canis lupus Species 0.000 abstract 1
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000030166 artemisia Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 50
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 238000005516 engineering process Methods 0.000 description 27
- 239000000843 powder Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 206010027514 Metrorrhagia Diseases 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 208000019255 Menstrual disease Diseases 0.000 description 13
- 208000000509 infertility Diseases 0.000 description 13
- 230000036512 infertility Effects 0.000 description 13
- 230000005906 menstruation Effects 0.000 description 13
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 10
- 208000021267 infertility disease Diseases 0.000 description 10
- 230000027758 ovulation cycle Effects 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 231100000535 infertility Toxicity 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000005171 Dysmenorrhea Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003821 menstrual periods Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 206010000210 abortion Diseases 0.000 description 5
- 231100000176 abortion Toxicity 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010008570 Chloasma Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000035568 catharsis Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 229940095686 granule product Drugs 0.000 description 3
- 238000007373 indentation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000005186 women's health Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 239000009557 Bak Foong Pill Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- PDNNQADNLPRFPG-UHFFFAOYSA-N N.[O] Chemical compound N.[O] PDNNQADNLPRFPG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100000548 menstrual delay Toxicity 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a tonifying capsule for women, which comprises (by weight parts) Chinese angelica root 2-20 parts, white atractylodes rhizome 4-25 parts, prepared rehmannia root 3-24 parts, rhizome of Sichuan lovage 2-15 parts, white peony root 2-20 parts, nutgrass flatsedge rhizome 2-15 parts, motherwort 2-16 parts, astragalus root 1-10 parts, eucommia bark 2-14 parts, Chinese mugwort leaf 2-16 parts, ophiopogon root 1-8 parts, donkey-hide gelatin 1-8 parts, licorice root 3-10 parts, dried orange peel 1-12 parts, poria cocos wolf 2-11 parts, amomum fruit 1-8 parts.
Description
Technical field
The invention belongs to the medicinal preparation technical field of the product that contains raw material or itself and not clear structure, be specifically related to derive from the material of plant.
Background technology
Insufficiency of vital energy and blood, stagnation of liver-QI do not relax, and menoxenia is had a dizzy spell, and blood leaks metrorrhagia, and the weak and infertility of anemia body is a commonly encountered disease.
The woman has a surplus in gas, is not enough to blood, blood stored in the liver, and main catharsis is " so the woman is congenital with liver ".The catharsis function of liver is normal, and then the mechanism of qi bar reaches, and blood is capable not idle; If feelings are not smooth, be worried, disgruntled, can cause depression of liver-QI, catharsis is not normal, disorder of QI and blood, chong-ren impairment causes menoxenia, and is of a specified duration and infertile.
The women is risen the eumenorrhea, and what lean on is that kidney essense is filled, and contains towards conception vessel, and QI and blood is full, unobstructed vessel.If the natural endowment deficiency, deficiency of qi and blood or stasis all can cause maiden's menstrual delay.Especially be retarded by silt with QI and blood, can not only make menoxenia, after the mistake, can cause dysmenorrhea, amenorrhea or metrorrhagia and metrostaxis again before catching up with, thus infertile.
The chloasma of women's facial appearance, grey brown patch, motherland's medical science are thought, are by due to the blood system stasis.The formation reason of congestion has the stagnation of QI, the deficiency of vital energy, heat in blood, cold in blood etc.Qi being the governor of blood, gas promoting the circulation of blood are also gone, qi depression to blood stasis; It is unable that the deficiency of vital energy is then transported blood, and the blood walking retardation in children stagnates, or the deficiency of vital energy blood of can not uniting, and the blood oozing from the body openings or subcuta neous tissue arteries and veins forms the stasis of blood outward; Cold having the property of contraction stagnates, and cold-evil visitor makes the blood vessel spasm in blood vessels, and blood is puckery with fixed attention, blood vessels operations does not freely form the stasis of blood: heat is gone into nutrient blood, and the rich knot of heat in blood stagnates the blood mucus and operation is not smooth, or the heat blood network that burns, the absurd row of forcing blood, escape of blood from meridians and overflowing between internal organs all can cause the stasis of blood.Congestion is pathological product, is again second cause of disease, can bring out multiple disease, as the heart angiopathy, and chloasma faciei, menoxenia, dysmenorrhea, infertile, the few warp of maiden, opsomenorrhea etc.People's face, venation are very abundant.QI and blood is filled Sheng, blood vessels tonneau, the gloss of then having rosy cheeks.If hematogenous blockage and being retarded by silt, then dim complexion dirt, or see purpura, or see chloasma, or grey brown patch etc. all can occur.
The Western medicine that is used for the treatment of gynaecopathia clinically has triphen oxygen ammonia, causes obesity after taking easily, takes for a long time to cause alopecia, ovarian tumor occurs.
The Chinese patent medicine that is used for the treatment of gynaecopathia clinically has tablet for women's health and tranquilness, the peaceful granule of woman, the peaceful syrup of dysmenorrhea.The tablet for women's health and tranquilness dosage is big, and reach 3 months the course of treatment, and onset is slow, is coated tablet, diabetes patient's forbidding.The peaceful granule dosage of woman is big, and the course of treatment is long, and onset is slow, is coated tablet, diabetes patient's forbidding.The peaceful syrup of dysmenorrhea is for containing sugared medicine, and the diabetes patient is forbidden, and product stability is poor, and dosage is big.
Summary of the invention
Technical problem to be solved by this invention is to overcome the shortcoming of said medicine, and a kind of Peroral solid dosage form medicine of treatment gynaecopathia evident in efficacy is provided.
It is with the following raw materials in weight portion Peroral solid dosage form medicament made of formulation method routinely to solve the problems of the technologies described above the technical scheme that adopted:
2～15 parts of 3～24 parts of Rhizoma Chuanxiongs of 4～25 parts of Radix Rehmanniae Preparata of 2～20 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
1～10 part of 2～16 parts of Radix Astragali of 2～15 parts of Herba Leonuris of 2～20 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
1～8 part in 2～14 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 1～8 part of Colla Corii Asini, 2～16 parts of Radix Ophiopogonis
1～8 part of 2～11 parts of Fructus Amomi of 1～12 part of Poria of 3～10 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
Preferred weight part proportion raw material of preparation medicine of the present invention is:
4～12 parts of 6～20 parts of Rhizoma Chuanxiongs of 8～20 parts of Radix Rehmanniae Preparata of 6～16 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
3～8 parts of 4～12 parts of Radixs Astragali of 4～12 parts of Herba Leonuris of 6～16 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
3～6 parts in 4～10 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 3～6 parts of Colla Corii Asini, 4～12 parts of Radix Ophiopogonis
3～6 parts of 4～10 parts of Fructus Amomis of 4～10 parts of Poria of 4～8 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
Optimum weight part proportion raw material of preparation medicine of the present invention is:
8 parts of 14 parts of Rhizoma Chuanxiongs of 12 parts of Radix Rehmanniae Preparata of 10 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
5 parts of 9 parts of Radixs Astragali of 8 parts of Herba Leonuris of 10 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
4 parts in 8 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 4 parts of Colla Corii Asini, 9 parts of Radix Ophiopogonis
4 parts of 8 parts of Fructus Amomis of 6 parts of Poria of 6 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
The Peroral solid dosage form medicament that above-mentioned each component is made according to a conventional method is said capsule or granule or tablet or a powder on the galenic pharmacy.
The preparation technology of medicine capsule of the present invention is as follows:
Get the Rhizoma Atractylodis Macrocephalae, Radix Rehmanniae Preparata, Rhizoma Chuanxiong, Herba Leonuri, the Radix Astragali, Rhizoma Cyperi, the Cortex Eucommiae, Folium Artemisiae Argyi, Radix Glycyrrhizae powder and be broken into coarse powder or section, decoct with water twice, add for the first time 10 times of water gagings, decocted 2 hours, for the second time add 8 times of water gagings, decocted 1 hour, merge decoction liquor twice, filter, filtrate is condensed into relative density 1.30～1.35 (20) thick paste; Colla Corii Asini joined in 4 times of water gagings of 40～50 ℃ dissolving and make the Colla Corii Asini aqueous solution, then the Colla Corii Asini aqueous solution is joined mixing in the above-mentioned thick paste, get Radix Angelicae Sinensis, Pericarpium Citri Reticulatae, Radix Ophiopogonis, Poria, Fructus Amomi, the Radix Paeoniae Alba and make 100 order fine powders,, add starch supplementary material and granulate cream, powder mixing, granulate, by the quality standard check of medicine capsule of the present invention, in after the ultraviolet disinfection sterilization, incapsulating, make capsule of the present invention, every heavy 0.35g, every gram is equivalent to crude drug in whole 2.514g.Proportioning raw materials that capsule is used and preparation technology press galenic pharmacy capsule proportioning raw materials preparation technology routinely and make.
The preparation technology of medicinal granule of the present invention is as follows:
The weight proportion of the raw material of Chinese medicine that the weight proportion of the raw material of Chinese medicine that medicinal granule of the present invention is used and medicine capsule of the present invention are used is identical, quality standard check by granule of the present invention, behind ultraviolet disinfection, pack in medicinal two wrong bag, every bag of 6g, every gram is equivalent to crude drug in whole 0.440g, warehouse-in.
The preparation technology of medicinal tablet of the present invention is as follows:
The weight proportion of the raw material of Chinese medicine that the weight proportion of the raw material of Chinese medicine that medicinal tablet of the present invention is used and medicine capsule of the present invention are used is identical, and used adjuvant and consumption are undertaken by the conventional preparation technology of tablet.Every heavy 0.5 gram, every gram is equivalent to crude drug in whole 2.640g.
The preparation technology of drug powder of the present invention is as follows:
The weight proportion of the raw material of Chinese medicine that the weight proportion of the raw material of Chinese medicine that drug powder of the present invention is used and medicine capsule of the present invention are used is identical, in the weight proportion of powder, do not add starch supplementary material, the preparation technology of drug powder of the present invention is undertaken by the conventional preparation technology of powder, every bag of 2.64g, every gram is equivalent to crude drug in whole 1g.
Bolus of drug of the present invention is vaginal hemorrhage 50 routine clinical observation tests after second the People's Hospital, Yinchuan City has carried out metrorrhagia 80 examples, menoxenia 90 examples, infertility 38 examples, medicine stream, result of the test shows among the bolus of drug treatment metrorrhagia 80 routine patients of the present invention, 40 examples of fully recovering account for 50%, produce effects 20 examples account for 25%, effective 16 examples account for 20%, invalid 4 examples account for 5%, and total effective rate is 95%; Among the treatment menoxenia 90 routine patients, 20 examples of fully recovering account for 22.22%, and produce effects 39 examples account for 43.33%, and effective 25 examples account for 27.78%, and invalid 6 examples account for 6.67%, and total effective rate is 93.33%; Among the treatment infertility 38 routine patients, pregnant 15 examples in primary sterility 28 examples, pregnant 3 examples in secondary sterility 10 examples, total effective rate is 47%, the 1 further consultation gestation person 4 example, the 2nd further consultation gestation 14 examples.Gestation result's bad (spontaneous abortion) 2 examples; Among the curative stream back vaginal hemorrhage 50 routine patients, 18 examples of fully recovering, produce effects 17 is imitated, effective 10 examples, invalid 5 examples, cure-remarkable-effectiveness rate is 70%, total effective rate is 90%.Medicine of the present invention can be promoted the use of after State Food and Drug Administration's approval is produced clinically.
The specific embodiment
The present invention is described in more detail below in conjunction with embodiment, but the invention is not restricted to these embodiment.
Embodiment 1
With 1000 of production capsule products of the present invention is that used raw material of example and weight proportion thereof are:
Radix Angelicae Sinensis 70.39g Rhizoma Atractylodis Macrocephalae 84.47g Radix Rehmanniae Preparata 98.55g Rhizoma Chuanxiong 56.31g
Radix Paeoniae Alba 70.39g Rhizoma Cyperi 56.31g Herba Leonuri 63.35g Radix Astragali 35.20g
Cortex Eucommiae 56.31g Folium Artemisiae Argyi 63.35g 28.16g Radix Ophiopogonis Colla Corii Asini 28.16g
Radix Glycyrrhizae 42.23g Pericarpium Citri Reticulatae 42.23g Poria 56.31g Fructus Amomi 28.16g
Starch adds to 350g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.35g, every gram is equivalent to crude drug in whole 2.514g, obeys each 3 every day three times.
With production granule product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Radix Angelicae Sinensis 35.20g Rhizoma Atractylodis Macrocephalae 42.24g Radix Rehmanniae Preparata 49.28g Rhizoma Chuanxiong 28.16g
Radix Paeoniae Alba 35.20g Rhizoma Cyperi 28.16g Herba Leonuri 31.68g Radix Astragali 17.60g
Cortex Eucommiae 28.16g Folium Artemisiae Argyi 31.68g 14.08g Radix Ophiopogonis Colla Corii Asini 14.08g
Radix Glycyrrhizae 21.12g Pericarpium Citri Reticulatae 21.12g Poria 28.16g Fructus Amomi 14.08g
Folium Stevlae Rebaudianae saponin 50g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 6g, every gram is equivalent to crude drug in whole 0.440g, obeys each 1 bag every day three times.
In the proportioning of present embodiment, the weight portion of each component of raw material of Chinese medicine is:
8 parts of 14 parts of Rhizoma Chuanxiongs of 12 parts of Radix Rehmanniae Preparata of 10 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
5 parts of 9 parts of Radixs Astragali of 8 parts of Herba Leonuris of 10 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
4 parts in 8 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 4 parts of Colla Corii Asini, 9 parts of Radix Ophiopogonis
4 parts of 8 parts of Fructus Amomis of 6 parts of Poria of 6 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
Embodiment 2
With 1000 of production capsule products of the present invention is that used raw material of example and weight proportion thereof are:
Radix Angelicae Sinensis 56.77g Rhizoma Atractylodis Macrocephalae 113.55g Radix Rehmanniae Preparata 85.16g Rhizoma Chuanxiong 56.77g
Radix Paeoniae Alba 56.77g Rhizoma Cyperi 56.77g Herba Leonuri 56.77g Radix Astragali 28.39g
Cortex Eucommiae 56.77g Folium Artemisiae Argyi 56.77g 28.39g Radix Ophiopogonis Colla Corii Asini 28.39g
Radix Glycyrrhizae 85.16g Pericarpium Citri Reticulatae 28.39g Poria 56.77g Fructus Amomi 28.39g
Starch adds to 350g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.35g, every gram is equivalent to crude drug in whole 2.514g, obeys each 3 every day three times.
With production granule product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Radix Angelicae Sinensis 28.38g Rhizoma Atractylodis Macrocephalae 56.76g Radix Rehmanniae Preparata 42.57g Rhizoma Chuanxiong 28.38g
Radix Paeoniae Alba 28.38g Rhizoma Cyperi 28.38g Herba Leonuri 28.38g Radix Astragali 14.19g
Cortex Eucommiae 28.38g Folium Artemisiae Argyi 28.38g 14.19g Radix Ophiopogonis Colla Corii Asini 14.19g
Radix Glycyrrhizae 42.57g Pericarpium Citri Reticulatae 14.19g Poria 28.38g Fructus Amomi 14.19g
Folium Stevlae Rebaudianae saponin 50g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 6g, every gram is equivalent to crude drug in whole 0.440g, obeys each 1 bag every day three times.
In the proportioning of present embodiment, the weight portion of each component of raw material of Chinese medicine is:
2 parts of 3 parts of Rhizoma Chuanxiongs of 4 parts of Radix Rehmanniae Preparata of 2 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
1 part of 2 parts of Radix Astragali of 2 parts of Herba Leonuris of 2 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
1 part in 2 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 1 part of Colla Corii Asini, 2 parts of Radix Ophiopogonis
1 part of 2 parts of Fructus Amomi of 1 part of Poria of 3 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
Embodiment 3
With 1000 of production capsule products of the present invention is that used raw material of example and weight proportion thereof are:
Radix Angelicae Sinensis 75.86g Rhizoma Atractylodis Macrocephalae 94.83g Radix Rehmanniae Preparata 91.03g Rhizoma Chuanxiong 56.90g
Radix Paeoniae Alba 75.86g Rhizoma Cyperi 56.90g Herba Leonuri 60.69g Radix Astragali 37.93g
Cortex Eucommiae 53.10g Folium Artemisiae Argyi 60.90g 30.34g Radix Ophiopogonis Colla Corii Asini 30.34g
Radix Glycyrrhizae 37.93g Pericarpium Citri Reticulatae 45.52g Poria 41.72g Fructus Amomi 30.34g
Starch adds to 350g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.35g, every gram is equivalent to crude drug in whole 2.514g, obeys each 3 every day three times.
With production granule product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Radix Angelicae Sinensis 37.93g Rhizoma Atractylodis Macrocephalae 47.41g Radix Rehmanniae Preparata 45.52g Rhizoma Chuanxiong 28.45g
Radix Paeoniae Alba 37.93g Rhizoma Cyperi 28.45g Herba Leonuri 30.34g Radix Astragali 18.97g
Cortex Eucommiae 26.55g Folium Artemisiae Argyi 30.34g 15.17g Radix Ophiopogonis Colla Corii Asini 15.17g
Radix Glycyrrhizae 18.97g Pericarpium Citri Reticulatae 22.76g Poria 20.86g Fructus Amomi 15.17g
Folium Stevlae Rebaudianae saponin 50g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of granule of the present invention.Every bag heavy 6g, every gram is equivalent to crude drug in whole 0.440g, obeys each 1 bag every day three times.
In the proportioning of present embodiment, the weight portion of each component of raw material of Chinese medicine is:
15 parts of 24 parts of Rhizoma Chuanxiongs of 25 parts of Radix Rehmanniae Preparata of 20 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
10 parts of 16 parts of Radixs Astragali of 15 parts of Herba Leonuris of 20 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
8 parts in 14 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 8 parts of Colla Corii Asini, 16 parts of Radix Ophiopogonis
8 parts of 11 parts of Fructus Amomis of 12 parts of Poria of 10 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
More than provided the weight proportion embodiment of capsule of the present invention and the used raw material of Chinese medicine of granule, the weight proportion of the used raw material of Chinese medicine of the weight proportion of the used raw material of Chinese medicine of capsule of the present invention applicable preparation identical weight medicinal tablet of the present invention, prepare the selection of the used adjuvant of medicinal tablet of the present invention and the proportioning and the preparation technology of adjuvant, the preparation technology of preparation method tablet carries out routinely, every heavy 0.5g, every gram is equivalent to crude drug in whole 2.640g, obeys each 2 every day three times.
The weight proportion of the used raw material of Chinese medicine of capsule of the present invention, the weight proportion of the used raw material of Chinese medicine of also applicable preparation identical weight drug powder of the present invention, in the weight proportion of powder, do not add starch supplementary material, the preparation technology of the preparation drug powder of the present invention preparation technology of preparation method powder routinely carries out, every bag of 2.64g, and every gram is equivalent to crude drug in whole 1g, obey each 1 bag every day three times.
In order to verify the therapeutic effect of medicine of the present invention to metrorrhagia, menoxenia, infertility, vaginal hemorrhage, the applicant will adopt the bolus of drug of the present invention (name is called the foster flourish ball of gynecological during test) of the embodiment of the invention 1 proportioning preparation to entrust second the People's Hospital, Yinchuan City to carry out the clinical observation test, and various test situation are as follows:
One, Drug therapy metrorrhagia 80 routine clinical observation tests of the present invention
1, clinical data
Test metrorrhagia 80 examples are selected to the outpatient, minimum 13 years old of age, maximum 50 years old, 13～25 years old 18 example wherein, 26～45 years old 37 example, 46～50 years old 25 example, the shortest person of the course of disease 20 days, elder 1 year.
2, diagnostic criteria and criterion of therapeutical effect
With reference to metrorrhagia disease in " Gynecology of Chinese Medicine " the 5th edition teaching material, dysfunctional uterine hemorrhage diagnostic criteria and " new drug tcm clinical practice research guideline " in the doctor trained in Western medicine " obstetrics and gynecology ".Clinical manifestation is the disorder in menstrual cycle and menstrual period, presents after irregular vagina bleeding or the short-term menstruation apolipsis hemorrhagely, and what indefinitely are point-like or bleed profusely more than amount of bleeding, color is light and matter is thin, and idol has clot, nervous breathing hard, fatigue and weak, pale complexion, idol has breast, lower abdominal distention pain.Light red tongue is fat, and there is indentation on the limit, white and thin fur, deep-thready pulse or thin and delicate.Be lower than normal value by the objective determination hematochrome, and get rid of the metrorrhagia that organic diseases such as systemic bleeding disease, genitals's tumor cause.
3, Therapeutic Method
Oral bolus of drug of the present invention, each 8 balls are equivalent to crude drug in whole 3 grams, and 3 times on the one, warm water delivery service.
4, criterion of therapeutical effect
Recovery from illness: menstrual cycle, menstrual period, amount, color recover normal, and keep 3 above persons of menstrual cycle; Produce effects: clinical symptoms and the sign person of having clear improvement; Effectively: clinical symptoms and sign make moderate progress; Invalid: clinical symptoms and sign do not have the improver.
5, therapeutic outcome
Recovery from illness 40 examples account for 50% in 80 routine patients, and produce effects 20 examples account for 25%, and effective 16 examples account for 20%, and invalid 4 examples account for 5%.Total effective rate 95%.
The sick type of typical case: the Wang, the woman, 37 years old, unemployed.First visit on February 14 in 2002.Patient's menorrhagia 1 year is surplus, dripping urine endlessly 20 days.In this year, menstrual cycle was normal though menstrual blood volume is many, and menstruation is this time risen unclean so far on January 24th, 2002, and many through measuring, color is light red, and idol has clot, companion's fatigue and weak, and the soreness of waist is stranded, poor appetite abdominal distention, pale complexion, there is indentation on the fat limit of light red tongue, white and thin fur, thready and weak pulse.The prompting of diagnosis pathologic finding: endometrial hyperplasia is long, routine blood test chemical examination, HGB70g/L, WBC4.5 * 10
9/ L, RBC3.4 * 10
12/ L.Western medicine diagnose: dysfunctional uterine hemorrhage.Tcm diagnosis: metrorrhagia, card belongs to deficient qi and blood, has the stagnation of liver-QI blood stasis concurrently.Control suitable benefiting qi and nourishing blood, dispersing the stagnated live-QI to relieve the stagnation of QI, blood stasis dispelling regulating menstruation.Flourish ball is supported by medicinal gynecological, and each 8 balls are equivalent to crude drug in whole 3 grams, and are every day 3 times, oral.Vaginal hemorrhage reduces gradually after taking medicine 7 days, and all proofs are apparent to be alleviated, and behind clothes 7 days, vaginal hemorrhage is ended, and all cards disappear.Advising clothes 2 menstrual cycle and fully recovering that continue, HGB returns to 115g/L by original 70g/L.Complicated after half a year with preventing.
Two, Drug therapy menoxenia 90 routine clinical observation tests of the present invention
1, clinical data
Test menoxenia 90 examples are selected to the outpatient, and differential diagnosis in tcm belongs to the deficiency in both Qi and blood stagnation of QI due to depression of the liver person that holds concurrently, and at 21～45 years old age, average 37 years old, the course of disease was the shortest 1 month, and is the longest 6 years, average 7 months.Many person's 63 examples of preceeded menorrhea amount, many person's 10 examples of delayed menstrual cycle amount, intermenstrual bleeding 8 examples, dysmenorrhea 4 examples, amenorrhea 5 examples.
2, diagnostic criteria and exclusion standard
Diagnostic criteria: disorder of menstrual cycle, intermenstrual bleeding, stomachache, menoxenia performance, accompanied symptoms is all with lustreless complexion, and is dizzy weak, palpitation and sleeplessness, mammary swelling uncomfortable in chest, the light red tongue tongue is few, the thready and weak pulse performance.The routine blood test chemical examination is below the hematochrome 100g/L.
Exclusion standard: menoxenia person due to genitals's tumor; The blood system pathological changes causes menoxenia person.
3, Therapeutic Method
Oral bolus of drug of the present invention, each 8, be equivalent to crude drug in whole 3 gram, one day 3 times are for oral administration, and eliminating cold for resuscitation water send down, and the clothes that continue menstrual period are judged curative effect after serveing on three menstrual cycle.
4, criterion of therapeutical effect
Be almost recovered: the main symptom of menopathy disappears (in menstrual period, the cycle normally or through measure normally or suffer from abdominal pain alleviation or vaginal hemorrhage ends), and accompanied symptoms is clearly better or disappears, and hematochrome rises to more than the 100g/L.
Produce effects: the main symptom and the accompanied symptoms of menopathy obviously improve, and hematochrome is normal.
Effectively: the main symptom and the accompanied symptoms of menopathy are clearly better.
Invalid: the basic no change of the main symptom of menopathy and accompanied symptoms.
5, therapeutic outcome
(1) how sick 63 examples of preceeded menorrhea amount: 17 examples of fully recovering, produce effects 28 examples, effective 16 examples, invalid 2 examples.
(2) delayed menstrual cycle 10 examples: 1 example of fully recovering, produce effects 3 examples, effective 6.
(3) intermenstrual bleeding 8 examples: recovery from illness 1, produce effects 7.
(4) dysmenorrhea 4 examples: 1 example of fully recovering, produce effects 1 example, effective 2.
(5) amenorrhea 5 examples: effective 1 example, invalid 4.
Model case: Lee *, the woman, 44 years old, the cadre, December in 1999 first visit on the 21st, preceding because of menorrhagia dripping not to the utmost surplus in the of 10 day in out-patient treatment, the row removal of intrauterine device.The postoperative menstruation still in advance and extremely, amount is many as annotate, color is light red, matter is rare, distention and pain of breast before menstruation is vexed, a sunshine is weak, the anorexia dry stool, menstruation now 10 days still unclean.In the amount, color is light red, and the light red tongue of body of the tongue is few, deep-thready pulse, lustreless complexion.Do not do pelvic cavity woman inspection temporarily because of hemorrhage, use the B-mode ultrasound tomography inspection, pelvic cavity no abnormality seen, the conventional hematochrome 98g/L that has a blood test, RBC304 ten thousand/L, WBC5.8/L, PC110 ten thousand/L.Tcm diagnosis, menorrhagia, card belongs to deficiency in both Qi and blood, the debility of CHONG and REN meridians, oral bolus of drug of the present invention, is equivalent to crude drug in whole 3 grams, 3 times on the one by each 8, menstruation is clean after taking medicine 5 days, and continue and take medicine to second round, menstruation 5 days in advance, clean through row 7 days, advising the clothes period 3 of continuing, menstruation comes at the appointed time, and is clean through row 7 days, medium through measuring, dizzy weak being clearly better, check hematochrome 110g/L, RBC384 ten thousand/L, efficacy determination is almost recovered.
Three, Drug therapy infertility 38 routine clinical observation tests of the present invention
1, clinical data
Test infertility 38 examples are selected to the outpatient, fertility person 28 examples wherein, infertility person 10 examples.At minimum 25 years old of age, maximum 32 years old, average 28 years old, the infertile time limit was the shortest 1 year, and was the longest 7 years, average 3.5 years.
2, diagnostic criteria
Women of child-bearing age man and wife lived together more than 2 years, and the syngamy function is normal, did not practise contraception and the person of not becoming pregnant; Or once bred, the person that becomes pregnant again more than 2 years practises contraception at the end.The fertility person gets rid of due to the congenital diseases, and the infertility person gets rid of due to genitals's organic disease.
3, Therapeutic Method
The oral bolus of drug of the present invention in the clean back of menstruation, each 8 material are equivalent to crude drug in whole 3 grams, and 3 times on the one, withdraw to menstrual onset, serve on 2 cycle further consultations 1 time, it is invalid that further consultation does not see that pregnant person judges for 2 times.Part patient adds vitamin E capsule, 1 time 2,1 time on the 1st.
4, therapeutic outcome
Pregnant 15 examples in this group primary sterility 28 examples, pregnant 3 examples in secondary sterility 10 examples, total effective rate 47%.The 1st further consultation gestation person 4 examples, the 2nd further consultation gestation 14 examples.Gestation result's bad (spontaneous abortion) 2 examples.
Model case: the Meng * *, the woman, 30 years old, the shop assistant, first visit on January 10 in 2000, the patient because of spontaneous abortion 1 tire after 2 years infertile existing delayed menstrual cyclees 6～7 days/35～37 days, light red through the amount polychrome, weigh down pain through the row lower abdomen, dizzy weak, receive the power loose stool.I also once had no result from the treatment of medicines such as clothes " WUJI BAIFENG WAN ", " training female ball " in pharmacy's work.So come my institute to seek medical advice.Woman's inspection, pudendum (-), vagina are smooth, in cervix uteri (-), palace body meta, normal big, the matter, activity, no tenderness, adnexa pair (-), leukorrhagia amount color no abnormality seen.Pale tongue is fat, and there is indentation on the limit, white and thin fur, and deep-thready pulse, tcm diagnosis: infertile, card belongs to insufficiency of vital energy and blood, and is not smooth towards appointing.Oral bolus of drug of the present invention, each 8, be equivalent to crude drug in whole 3 gram, one day 3 times, withdraw menstrual period, through the row clothes that continued in 5 days.This routine patient takes medicine second round, menstruation as scheduled not extremely, menolipsis 45 days, the urine test HCG positive.The pelvic cavity B ultrasonic confirms uterine pregnancy.Advise the attention antenatal care.
Four, pharmacotherap stream back vaginal hemorrhage 50 routine clinical observation tests of the present invention
1, clinical data
Investigational agent stream back vaginal hemorrhage 50 examples are selected to the outpatient, all are urine HCG (+) before the drug induced abortion, and the B-mode ultrasound tomography inspection turns out to be uterine pregnancy, and foetal sac diameter≤3.0CM, and blood routine examination is normal, and other condition all meets the medicine standard of failing to be sold at auction.Do for the first time 32 examples of drug induced abortion in 50 examples, do 18 examples of drug induced abortion for the second time, the age is 22～30 years old 28 example, 31～40 years old 22 example.
2, Therapeutic Method
After drug induced abortion is discharged foetal sac, oral bolus of drug of the present invention, each 8 balls are equivalent to crude drug in whole 3 grams, and 3 times on the one, warm water delivery service.
3, criterion of therapeutical effect
Recovery from illness: taking medicine, vaginal hemorrhage stops in back 7 days; Produce effects: take medicine the back 8～10 days in vaginal hemorrhage stop; Effectively: the back vaginal hemorrhage on the 10th～14 of taking medicine stops; Invalid: the back of taking medicine surpasses 15 days or will do clearing heat in the pericardium operation because of going out hyperhematosis.
4, therapeutic outcome
18 examples of fully recovering, produce effects 17 is imitated effective 10 examples, invalid 5 examples.Cure-remarkable-effectiveness rate 70%, total effective rate 90%.
Model case: Ma, the woman, 26 years old, the workman was in first visit on April 10 in 2000.Patient's menolipsis 48 days, last menstrual period on February 22nd, 2000, with dizziness, nausea and vomiting, fatigue and weak, the HCG (+) that has urine examined, B-mode ultrasound tomography inspection are uterine pregnancy, and the foetal sac size is 2.8 * 2.5cm, and blood routine examination is normal, is diagnosed as early pregnancy.After drug induced abortion is discharged foetal sac, oral bolus of drug of the present invention, each 8 balls are equivalent to crude drug in whole 3 grams, 3 times on the one.Vaginal hemorrhage stops in 7 days, and health is good, the 2nd month menstruation tide that comes in time.
Function of the present invention: invigorating QI and blood, dispersing the stagnated live-QI to relieve the stagnation of QI, blood stasis dispelling regulating menstruation.
The present invention cures mainly: be used for that insufficiency of vital energy and blood, stagnation of liver-QI are not relaxed, menoxenia, have a dizzy spell, blood leaks metrorrhagia, the anemia body is weak and infertility.
Specification of the present invention: every heavy 0.35g of medicine capsule of the present invention, every gram is equivalent to crude drug in whole 2.514g; Every bag heavy 6g of medicinal granule of the present invention, every gram is equivalent to crude drug in whole 0.440g; Every bag heavy 2.640g of drug powder of the present invention, every gram is equivalent to crude drug in whole 1g; Every heavy 0.5g of medicinal tablet of the present invention, every gram is equivalent to crude drug in whole 2.640g.
Usage and dosage of the present invention: obey every day three times, obey 2 in 1 bag of 1 bag of 3 of capsules or granule or powder or tablet at every turn.
Points for attention of the present invention: the medication period pungent stimulation food of avoiding eating anything raw or cold.
Storage of the present invention: the shady and cool dry place of sealing storage.
Effect duration of the present invention: 2 years.
Claims (3)
1, flourish capsule is supported by a kind of gynecological, it is characterized in that it is by the following weight parts proportion raw material medicament of formulation method preparation routinely:
2～15 parts of 3～24 parts of Rhizoma Chuanxiongs of 4～25 parts of Radix Rehmanniae Preparata of 2～20 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
1～10 part of 2～16 parts of Radix Astragali of 2～15 parts of Herba Leonuris of 2～20 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
1～8 part in 2～14 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 1～8 part of Colla Corii Asini, 2～16 parts of Radix Ophiopogonis
1～8 part of 2～11 parts of Fructus Amomi of 1～12 part of Poria of 3～10 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
2, support flourish capsule according to the described gynecological of claim 1, it is characterized in that wherein the weight portion proportioning of each raw material is:
4～12 parts of 6～20 parts of Rhizoma Chuanxiongs of 8～20 parts of Radix Rehmanniae Preparata of 6～16 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
3～8 parts of 4～12 parts of Radixs Astragali of 4～12 parts of Herba Leonuris of 6～16 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
3～6 parts in 4～10 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 3～6 parts of Colla Corii Asini, 4～12 parts of Radix Ophiopogonis
3～6 parts of 4～10 parts of Fructus Amomis of 4～10 parts of Poria of 4～8 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
3, support flourish capsule according to the described gynecological of claim 1, it is characterized in that wherein the weight portion proportioning of each raw material is:
8 parts of 14 parts of Rhizoma Chuanxiongs of 12 parts of Radix Rehmanniae Preparata of 10 parts of Rhizoma Atractylodis Macrocephalaes of Radix Angelicae Sinensis
5 parts of 9 parts of Radixs Astragali of 8 parts of Herba Leonuris of 10 portions of Rhizoma Cyperis of the Radix Paeoniae Alba
4 parts in 8 portions of Folium Artemisiae Argyis of the Cortex Eucommiae, 4 parts of Colla Corii Asini, 9 parts of Radix Ophiopogonis
4 parts of 8 parts of Fructus Amomis of 6 parts of Poria of 6 parts of Pericarpium Citri Reticulataes of Radix Glycyrrhizae
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100263338A CN100333782C (en) | 2004-07-16 | 2004-07-16 | Female nutritive tonic capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100263338A CN100333782C (en) | 2004-07-16 | 2004-07-16 | Female nutritive tonic capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1720977A true CN1720977A (en) | 2006-01-18 |
| CN100333782C CN100333782C (en) | 2007-08-29 |
Family
ID=35911814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100263338A Expired - Lifetime CN100333782C (en) | 2004-07-16 | 2004-07-16 | Female nutritive tonic capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100333782C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647901B (en) * | 2009-04-16 | 2011-08-17 | 原枫 | Oral Chinese herba preparation for treating postpartum qi and blood deficiency of woman and production method thereof |
| CN102210834A (en) * | 2011-05-15 | 2011-10-12 | 姜元芳 | Chinese medicine for treating irregular menstrual period |
| CN102319317A (en) * | 2011-08-15 | 2012-01-18 | 江苏苏南药业实业有限公司 | Traditional Chinese medicine composition for treating menstrual disorder and preparation method thereof |
| CN101564463B (en) * | 2009-05-27 | 2012-04-25 | 姜红 | Medicament for treating functional uterine hemorrhage |
| CN104667130A (en) * | 2015-03-19 | 2015-06-03 | 任甜甜 | Traditional Chinese medicinal preparation for treating menstrual cycle disorder and preparation method for traditional Chinese medicinal preparation |
| CN104800782A (en) * | 2014-01-26 | 2015-07-29 | 山东省医学科学院基础医学研究所 | Traditional Chinese medicine for treatment of post-abortion endometrorrhagia and preparation method thereof |
| CN105267838A (en) * | 2015-10-16 | 2016-01-27 | 滨州市人民医院 | Oral medication for benefiting qi and nourishing blood after childbirth |
| CN108853420A (en) * | 2018-09-17 | 2018-11-23 | 山西省人民医院 | Treat the barrenness caused Chinese medicine of polycystic ovary |
| CN114306549A (en) * | 2022-01-18 | 2022-04-12 | 云南省中医医院(云南中医药大学第一附属医院) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type viscera dysfunction, preparation and application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1124153A (en) * | 1994-12-06 | 1996-06-12 | 蒋正文 | Medicine for recovery and replenishing liver and its preparing method |
| CN1181959A (en) * | 1997-07-09 | 1998-05-20 | 迟经惠 | Yin nourishing bolus for curing women's blood deficiency |
-
2004
- 2004-07-16 CN CNB2004100263338A patent/CN100333782C/en not_active Expired - Lifetime
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647901B (en) * | 2009-04-16 | 2011-08-17 | 原枫 | Oral Chinese herba preparation for treating postpartum qi and blood deficiency of woman and production method thereof |
| CN101564463B (en) * | 2009-05-27 | 2012-04-25 | 姜红 | Medicament for treating functional uterine hemorrhage |
| CN102210834A (en) * | 2011-05-15 | 2011-10-12 | 姜元芳 | Chinese medicine for treating irregular menstrual period |
| CN102319317A (en) * | 2011-08-15 | 2012-01-18 | 江苏苏南药业实业有限公司 | Traditional Chinese medicine composition for treating menstrual disorder and preparation method thereof |
| CN104800782A (en) * | 2014-01-26 | 2015-07-29 | 山东省医学科学院基础医学研究所 | Traditional Chinese medicine for treatment of post-abortion endometrorrhagia and preparation method thereof |
| CN104667130A (en) * | 2015-03-19 | 2015-06-03 | 任甜甜 | Traditional Chinese medicinal preparation for treating menstrual cycle disorder and preparation method for traditional Chinese medicinal preparation |
| CN105267838A (en) * | 2015-10-16 | 2016-01-27 | 滨州市人民医院 | Oral medication for benefiting qi and nourishing blood after childbirth |
| CN108853420A (en) * | 2018-09-17 | 2018-11-23 | 山西省人民医院 | Treat the barrenness caused Chinese medicine of polycystic ovary |
| CN114306549A (en) * | 2022-01-18 | 2022-04-12 | 云南省中医医院(云南中医药大学第一附属医院) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type viscera dysfunction, preparation and application |
| CN114306549B (en) * | 2022-01-18 | 2023-03-28 | 云南省中医医院(云南中医药大学第一附属医院) | Traditional Chinese medicine composition for improving joint movement function after hip replacement surgery and relieving postoperative pain, preparation and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100333782C (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1915399A (en) | Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method | |
| CN1720977A (en) | Female nutritive tonic capsule | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1255154C (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN100509034C (en) | Medicine for treating chronic atrophic gastritis | |
| CN114344422B (en) | Traditional Chinese medicine composition for preventing and treating postoperative constipation caused by qi and blood deficiency and intestinal dryness and application thereof | |
| CN109045162A (en) | Chinese medicine composition and its application for treating endometriosis | |
| CN1726991A (en) | Medication of treating by dysenorrhea, irregular menses, weakness after childbirth for women, and preparation method | |
| CN1785292A (en) | Medicine for treating flooding and spotting and its preparation method | |
| CN102988892A (en) | Medicament for treating hysteromyoma and ovarian cysts | |
| CN101954046B (en) | Medicament for treating hyperplasia of mammary glands | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1217680C (en) | Repellent mixture for department of gynecology | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN112741888B (en) | A kind of traditional Chinese medicine composition for treating embryo stop disease and its application | |
| CN1290547C (en) | Traditional Chinese medicine for treating and preventing high blood pressure and its preparation technology | |
| CN102357179B (en) | Medicine for treating antisperm antibody induced infertility or habitual abortion and preparation method thereof | |
| CN105535466A (en) | Pharmaceutical composition for treating pubescent polycystic ovarian syndrome | |
| CN104706882A (en) | Traditional Chinese medicine preparation for treating qi stagnancy and blood stasis type postmenopausal osteoporosis | |
| CN117205230A (en) | The use of deer blood crystals in the preparation of drugs for treating thin endometrium and improving endometrium and uterine artery blood supply | |
| CN109288953A (en) | A kind of Chinese herbs paste tonified the kidney and support yang | |
| CN1772074A (en) | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying | |
| CN1709448A (en) | Tibetan medicine for treating women's diseases, and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20111213 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2011990000489 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130201 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2011990000489 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20130201 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2013990000078 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140418 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2013990000078 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20140421 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2014990000280 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150521 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2014990000280 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20150527 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2015990000397 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160627 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2015990000397 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20160627 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Electronic City Branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2016990000537 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180117 Granted publication date: 20070829 Pledgee: Bank of Xi'an Limited by Share Ltd. Xi'an Yanta military and civilian integration branch Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2016990000537 |
|
| PM01 | Change of the registration of the contract for pledge of patent right | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20180117 Registration number: 2016990000537 Pledgee after: Bank of Xi'an Limited by Share Ltd. Xi'an Yanta military and civilian integration branch Pledgee before: Bank of Xi'an Limited by Share Ltd. Electronic City Branch |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Female nutritive tonic capsule Effective date of registration: 20180925 Granted publication date: 20070829 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2018990000865 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221014 Granted publication date: 20070829 Pledgee: Xi'an innovation financing Company limited by guarantee Pledgor: XI'AN ANDE PHARMACEUTICAL CO.,LTD. Registration number: 2018990000865 |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070829 |